Laura Stoppel is a Principal on the Investment Team at RA Capital Management. Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, Indapta Therapeutics, and Acumen Pharmaceuticals. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.
Speaking In
3:30 PM - 4:30 PM
Monday, June 5
